Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options
placeholder image
Publications in VIVO
 
    Export Publications Table
co-author
Co-author Network
map of science
Map of Science

Balog, C.

share the uri
  • Publications
scroll to property group menus

Publications

recent publications

  • academic article

    • Blankenship, J. C., Balog, C., Sapp, S. K., Califf, R. M., Lincoff, A. M., Tcheng, J. E., Topol, E. J. Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials Catheterization and Cardiovascular Interventions  2002 57:476-483  DOI:10.1002/ccd.10322  PMID:12455081
    • Islam, M. A., Blankenship, J. C., Balog, C., Iliadis, E. A., Lincoff, M., Tcheng, J. E., Califf, R. M., Topol, E. J., Investigators, Epistent Effect of abciximab on angiographic complications during percutaneous coronary stenting in the evaluation of platelet iib/iiia inhibition in stenting trial (epistent) American Journal of Cardiology  2002 90:916-921  DOI:10.1016/s0002-9149(02)02653-x  PMID:12398954
    • Mazur, W., Kaluza, G. L., Sapp, S., Balog, C., Topol, E. J., Mark, D. B., Ellis, S. G., Kereiakes, D. J., Lincoff, A. M., Kleiman, N. S. Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists American Heart Journal  2002 143:594-601  DOI:10.1067/mhj.2002.121519  PMID:11923795
    • Akkerhuis, K. M., Deckers, J. W., Lincoff, A. M., Tcheng, J. E., Boersma, E., Anderson, K., Balog, C., Califf, R. M., Topol, E. J., Simoons, M. L. Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention JAMA-Journal of the American Medical Association  2001 286:78-82  DOI:10.1001/jama.286.1.78  PMID:11434830
    • Cho, L., Topol, E. J., Balog, C., Foody, J. M., Booth, J. E., Cabot, C., Kleiman, N. S., Tcheng, J. E., Califf, R., Lincoff, M. A. Clinical benefit of glycoprotein iib/iiia blockade with abciximab is independent of gender - pooled analysis from epic, epilog and epistent trials Journal of the American College of Cardiology  2000 36:381-386  DOI:10.1016/s0735-1097(00)00746-4  PMID:10933346
    • Lincoff, A. M., Tcheng, J. E., Califf, R. M., Kereiakes, D. J., Kelly, T. A., Timmis, G. C., Kleiman, N. S., Booth, J. E., Balog, C., Cabot, C. F., Anderson, K. M., Weisman, H. F., et al. Sustained suppression of ischemic complications of coronary intervention by platelet gp iib/iiia blockade with abciximab - one-year outcome in the epilog trial Circulation  1999 99:1951-1958  PMID:10208997
    • Topol, E. J., Lincoff, A. M., Califf, R. M., Tcheng, J. E., Kleiman, N. S., Adelman, A. G., Burton, J. R., Talley, J. D., Ivanhoe, R. J., Ducas, C., Cheung, P. K., Schick, U., et al. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade Lancet  1998 352:87-92  DOI:10.1016/s0140-6736(98)85010-1  PMID:9672272

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support